uniQure Secures $242.7M in Upsized Stock Offering at $45.50 Per Share
Summary
uniQure has finalized its upsized public offering, securing $242.7 million in net proceeds by selling shares at $45.50 each. This includes the full exercise of the underwriters' option. The financing follows recent positive regulatory and clinical updates for the company's gene therapy pipeline, providing substantial capital to advance its programs. While dilutive, this strengthens the balance sheet for a biotech with active development.
At the time of this announcement, QURE was trading at $49.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $8.73 to $71.50. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.